Dermatology News

With Kim Kardashian speaking out about her son’s experience with vitiligo, Healio Dermatology sat with an expert to discuss the condition in the adult and pediatric populations.

A higher risk for developing psoriasis was found in subjects who were fed formula as infants compared with those who were breastfed for at least the first 4 months of life, according to a Swedish study.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.

Clascoterone cream 1% caused mild, reversible hypothalamic-pituitary-adrenal axis suppression under maximum-use exposure in patients with acne vulgaris, according to a study.

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel demonstrated safety and efficacy across all age groups for the treatment of acne, according to a post hoc analysis.

We checked in with CDC Director Mandy K. Cohen, MD, MPH, for an update on the agency’s efforts to modernize the nation’s disease surveillance and data systems and improve how the CDC communicates with the public and physicians.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.